The primary objective was assessment of the clinical and laboratory safety of F ( ab ' ) , which was monitored for @ days in the group that received one dose ( assessments on days @-@ , @ , @ , @ , and @ ) and @ days in the group that received five doses ( days @-@ , @ , @ , @ , @ , @ , and @ ) .